FDA approves Eli Lilly's tirzepatide for weight loss, paving way for wider use of blockbuster drug

The obesity approval further establishes Eli Lilly as a formidable competitor to Novo Nordisk in the budding weight loss drug industry.

from Health and Science https://ift.tt/AS3KWL7
https://ift.tt/oynzEWM
https://ift.tt/70eFng6